Pain and palliative care treatment in daily practice

Summary

In addition to other distressing symptoms, palliative patients often suffer from very severe pain. For this reason, a precise pain diagnosis is necessary in order to be able to initiate the necessary therapeutic measures. Pain therapy includes the medications specified in the World Health Organization (WHO) analgesic ladder as well as various supportive measures.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Smith AK, et al. The epidemiology of pain during the last 2 years of life. Ann Intern Med. 2010;153:563–9.

    Article  Google Scholar 

  2. 2.

    Gill TM, Han L, Leo-Summers L, Gahbauer EA, All-ore HG. Distressing symptoms, disability, and hospice services at the end of life: prospective cohort study. J Am Geriatr Soc. 2018;66(1):41–7. https://doi.org/10.1111/jgs.15041.

    Article  PubMed  Google Scholar 

  3. 3.

    Bostwick D, Wolf St, Samsa G, et al. Comparing the palliative care needs of those with cancer to those with common non-cancer serious illness. J Pain Symptom Manage. 2017;53(6):1079–1084.e1.

    Article  Google Scholar 

  4. 4.

    Köstenberger M, Neuwersch S, Weixler D, Pipam W, Zink M, Likar R. Prevalence of palliative care patients in emergency departments. Wien Klin Wochenschr. 2019;131(17–18):404–9. https://doi.org/10.1007/s00508-019-1530-5.

    Article  PubMed  Google Scholar 

  5. 5.

    World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. CC BY-NC-SA 3.0 IGO. Geneva: WHO; 2018.

    Google Scholar 

  6. 6.

    Anekar AA, Cascella M. WHO analgesic ladder. 2020. https://www.ncbi.nlm.nih.gov/books/NBK554435/. Accessed 17 May 2020.

  7. 7.

    https://www.basg.gv.at/fileadmin/redakteure/06_Gesundheitsberufe/DHPC/2013/131028_Diclofenac-1.pdf. Accessed 24 Jan 2021.

  8. 8.

    European Medicines Agency. PRAC recommends the samecardiovascular precautions for diclofenac as for selective COX‑2 inhibitors. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144451.pdf. Accessed 24 Jan 2021.

  9. 9.

    European Medicines Agency. New safety advice for diclofenac. New measures aim to minimise cardiovascular risks. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diclofenaccontaining_medicinal_products/European_Commission_final_decision/WC500155819.pdf. Accessed 24 Jan 2021.

  10. 10.

    European Medicines Agency. PRAC recommends updating advice on use of high-dose ibuprofen. Review confirms small increased cardiovascular risk with daily doses at or above 2,400 mg. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/04/WC500185426.pdf. Accessed 24 Jan 2021.

  11. 11.

    Reinecke H, Sorgatz H. S3 guideline LONTS. Long-term administration of opioids for non-tumor pain. Schmerz. 2009;23(5):440–7. https://doi.org/10.1007/s00482-009-0839-9.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Heiskanen T, Mätzke S, Haakana S, Gergov M, Vuori E, Kalso E. Transdermal fentanyl in cachectic cancer patients. Pain. 2009;144(1–2):218–22. https://doi.org/10.1016/j.pain.2009.04.012.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Chiba T, Takahashi H, Tairabune T, Kimura S, Ueda H, Kudo K. Cancer cachexia may hinder pain control when using fentanyl patch. Biol Pharm Bull. 2020;43(5):873–8. https://doi.org/10.1248/bpb.b19-01086.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Sittl R, Likar R, Nautrup PB. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther. 2005;27(2):225–37.

    CAS  Article  Google Scholar 

  15. 15.

    Wilcock A, Charlesworth S, Toller CS, Girish R, Mihalyo M, Howard P. Denosumab: AHFS 92:24. J Pain Symptom Manage. 2018;56(2):295–301. https://doi.org/10.1016/j.jpainsymman.2018.05.021.

    Article  PubMed  Google Scholar 

  16. 16.

    Porta-Sales J, Garzón-Rodríguez C, Llorens-Torromé S, Brunelli C, Pigni A, Caraceni A. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project. Palliat Med. 2017;31(1):5–25. https://doi.org/10.1177/0269216316639793.

    Article  PubMed  Google Scholar 

  17. 17.

    Rasche T, Emmert D, Radbruch L, et al. Cannabis und Cannabinoide in der Palliativversorgung. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019;62:830–5. https://doi.org/10.1007/s00103-019-02967-1.

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dr. Markus Köstenberger.

Ethics declarations

Conflict of interest

M. Köstenberger and R. Likar declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Köstenberger, M., Likar, R. Pain and palliative care treatment in daily practice. memo (2021). https://doi.org/10.1007/s12254-021-00685-6

Download citation

Keywords

  • Tumor pain
  • NSAR
  • Opioid therapy
  • Supportive therapy
  • WHO therapy scheme